L2 Asset Management LLC Has $5.84 Million Stake in United Therapeutics Corporation $UTHR

L2 Asset Management LLC decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 16.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,989 shares of the biotechnology company’s stock after selling 2,334 shares during the period. L2 Asset Management LLC’s holdings in United Therapeutics were worth $5,842,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in UTHR. Darwin Global Management Ltd. acquired a new position in United Therapeutics in the third quarter worth approximately $317,617,000. Norges Bank acquired a new position in United Therapeutics in the fourth quarter worth approximately $293,418,000. Baillie Gifford & Co. acquired a new position in United Therapeutics in the fourth quarter worth approximately $157,390,000. Balyasny Asset Management L.P. increased its holdings in United Therapeutics by 863.9% in the second quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock worth $43,886,000 after buying an additional 136,883 shares during the last quarter. Finally, Victory Capital Management Inc. increased its holdings in United Therapeutics by 108.1% in the fourth quarter. Victory Capital Management Inc. now owns 228,383 shares of the biotechnology company’s stock worth $111,280,000 after buying an additional 118,628 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on UTHR shares. HC Wainwright increased their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Bank of America upped their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Raymond James Financial started coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $541.39, for a total value of $5,143,205.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $21,933,333.07. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $549.29, for a total transaction of $5,492,900.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,368,398.04. The trade was a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 634,468 shares of company stock valued at $357,970,302. 8.60% of the stock is owned by company insiders.

United Therapeutics Stock Up 0.7%

Shares of United Therapeutics stock opened at $549.57 on Tuesday. The stock has a market capitalization of $23.33 billion, a P/E ratio of 20.29, a PEG ratio of 1.78 and a beta of 0.57. The stock has a 50 day moving average price of $566.45 and a two-hundred day moving average price of $522.10. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company earned $6.63 EPS. Sell-side analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.